Free Trial
NASDAQ:GRCE

Grace Therapeutics Q4 2025 Earnings Report

Grace Therapeutics logo
$2.97 0.00 (0.00%)
As of 05/23/2025 03:48 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.23
Beat/Miss
N/A
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, June 23, 2025
Conference Call Time
9:30AM ET

Conference Call Resources

Grace Therapeutics Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat